Impact of Online Patient Feedback (OQ) to Therapist

January 23, 2024 updated by: Espen Walderhaug, Oslo University Hospital

Addiction Treatment Dropout Prevention - Impact of Online Patient Feedback (OQ-45.2) to Therapist

Dropout represents one of the largest problems in substance abuse treatment. International and Nordic research show that only 20 - 40 % of substance abusers complete treatment as intended. At the same time, one of the most consistent factors of favourable post-treatment outcome is treatment completion. In spite of the serious and continuous challenge dropout represents the phenomena is not well understood and there is a need to explore more of the factors that influence dropout and how it can be counteracted. As also stated: "…effective methods for reducing the problem of dropouts from treatment is one more area in need of further research" (NOU 2003:4, s 77).

For the general field of mental health one of the most important innovations involves providing therapists with patient feedback about their progress. The most well-established and widely researched feedback system is the Outcome Questionnaire (OQ-45.2). The system has been shown to improve treatment outcomes, including reduced treatment dropout and length of treatment, but the system is yet to be utilized with a substance abusing patient group. The aim of the present study is to examine the usefulness of OQ-45.2 with substance abusing patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hypotheses and research questions

1. The OQ-45.2 feedback will be effective in identifying patients at risk of dropout of substance abuse treatment.

1a. The condition were feedback is withheld from the therapist, will correctly identify patients who will dropout.

Research Question: Is there variation in the accuracy of dropout prediction as a function of age, gender differences or type of substance abuse?

2. The OQ-45.2 feedback will be effective in reducing dropout in outpatient substance abuse treatment.

2a. The feedback condition will result in less dropout than the no-feedback condition.

Research Question: Is there a variation in the OQ-45.2 preventive dropout effect due to age, gender or type of substance abuse?

3. The OQ-45.2 feedback will shorten length of inpatient substance abuse treatment.

3a. The feedback condition will identify patients who are ready to terminate therapy.

Research Question: Is there variation in identification of patients ready to terminate as a function of age, gender differences or type of substance abuse?

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
      • Oslo, Norway, 0514
        • Department of addiction treatment- youth
      • Oslo, Norway, 0514
        • Oslo University Hospital - Department of addiction treatment youth

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 26 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Primary diagnosis of addiction, F10-19, using the International Classification of Diseases, admitted in 2011-2014 for treatment at the department of addiction treatment - youth, Oslo University Hospital

Exclusion Criteria:

  • Ongoing psychoses, severe language difficulties

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Patients merely monitored on background variables to function as a baseline of comparison
Active Comparator: Prediction
Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
Behavioral: OQ-45.2 no feedback
Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
Experimental: Intervention
Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
Behavioral: OQ-45.2
Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Drop-out from residential SUD treatment
Time Frame: Four years
Exit reason from residential Substance Use Disorder treatment (Drop-out or completed as planned)
Four years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Oslo University Hospital

Collaborators

University of Oslo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2011

Primary Completion (Actual)

November 1, 2014

Study Completion (Actual)

January 3, 2023

Study Registration Dates

First Submitted

July 6, 2012

First Submitted That Met QC Criteria

June 27, 2013

First Posted (Estimated)

July 2, 2013

Study Record Updates

Last Update Posted (Estimated)

January 24, 2024

Last Update Submitted That Met QC Criteria

January 23, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OQ45-11-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Drug Abuse

Clinical Trials on OQ-45.2 no feedback

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe